Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

iTeos Therapeutics Inc
Healthcare
P/NCAV
0.86x
Ticker
ITOS
Exchange
NASDAQ
Country
United States
Close
10.99 $
Mkt Cap
393.0M $
EV
141.9M $
NCAV Burn Rate
14.6%
Current Ratio
13.76
Debt/Equity
0.0
EV/REV
11.26x
EV/EBIT
-0.9x
EV/FCF
-1.4x
Dilution
1.4% p.A
Total Net Income
120.0M $
Cheapness
100.0%
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average